2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, Fanikos J, Connors J, Siegal D, Barnes G, Martin K, Angiolillo D, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind M, Ruff C, Goldhaber S, Krumholz H, Mehran R, Cushman M, Eikelboom J, Lip G, Weitz J, Lopes R, Bikdeli B. When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 444-465. PMID: 38233019, DOI: 10.1016/j.jacc.2023.10.038.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsStandard of careRandomized controlled trialsOral anticoagulantsAtrial fibrillationCatheter-associated deep vein thrombosisCerebral venous sinus thrombosisControlled trialsVitamin K antagonistsThrombotic antiphospholipid syndromeEnd-stage renal diseaseLeft ventricular thrombusVenous thromboembolism treatmentVenous sinus thrombosisDeep vein thrombosisRheumatic heart diseaseReview of randomized controlled trialsEvidence-based reviewK antagonistsAntiphospholipid syndromeSinus thrombosisVentricular thrombusVein thrombosisThromboembolism treatmentVenous thrombosis
2022
Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
Noseworthy PA, Van Houten HK, Krumholz HM, Kent DM, Abraham NS, Graff‐Radford J, Alkhouli M, Henk HJ, Shah ND, Gersh BJ, Friedman PA, Holmes DR, Yao X. Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation. Journal Of The American Heart Association 2022, 11: e027001. PMID: 36172961, PMCID: PMC9673739, DOI: 10.1161/jaha.121.027001.Peer-Reviewed Original ResearchConceptsComposite end pointAtrial appendage occlusionOral anticoagulantsAtrial fibrillationLower riskMajor bleedingSystemic embolismIntracranial bleedingAppendage occlusionNon-Vitamin K Antagonist Oral AnticoagulantsIschemic stroke/systemic embolismK Antagonist Oral AnticoagulantsPrimary composite end pointPropensity score overlap weightingStroke/systemic embolismEnd pointHigh bleeding riskSignificant differencesAntithrombotic regimensBleeding riskCause mortalityBaseline characteristicsComposite outcomeIschemic strokeSecondary outcomesEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsAtrial FibrillationDabigatranHumansRivaroxabanStrokeVenous ThromboembolismConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patientsAssociation of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study
Abdel-Qadir H, Akioyamen LE, Fang J, Pang A, Ha ACT, Jackevicius CA, Alter DA, Austin PC, Atzema CL, Bhatia RS, Booth GL, Johnston S, Dhalla I, Kapral MK, Krumholz HM, McNaughton CD, Roifman I, Tu K, Udell JA, Wijeysundera HC, Ko DT, Schull MJ, Lee DS. Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study. Circulation 2022, 146: 159-171. PMID: 35678171, PMCID: PMC9287095, DOI: 10.1161/circulationaha.122.058949.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationCohort StudiesDelivery of Health CareFemaleHeart FailureHemorrhageHumansMaleOntarioRisk FactorsStrokeConceptsYears of ageCohort studyUniversal health careAF-related adverse eventsNeighbourhood-level material deprivationPopulation-based cohort studyPrimary care physician visitsCause-specific hazards regressionRhythm control interventionsHigh cardiovascular disease burdenCardiovascular disease burdenHealth careAtrial fibrillation careNeighborhood material deprivationSingle-payer health care systemMaterial deprivation quintileAtrial fibrillation diagnosisHealth care systemNoncardiovascular comorbiditiesAdverse eventsHeart failurePhysician visitsHazards regressionAdverse outcomesDeprivation quintileInstitutional Variation in 30‐Day Complications Following Catheter Ablation of Atrial Fibrillation
Ngo L, Ali A, Ganesan A, Woodman R, Krumholz HM, Adams R, Ranasinghe I. Institutional Variation in 30‐Day Complications Following Catheter Ablation of Atrial Fibrillation. Journal Of The American Heart Association 2022, 11: e022009. PMID: 35156395, PMCID: PMC9245833, DOI: 10.1161/jaha.121.022009.Peer-Reviewed Original ResearchConceptsProcedure-related complicationsComplication rateAF ablationAtrial fibrillationCatheter ablationStroke/transient ischemic attackCare qualityTransient ischemic attackRisk of complicationsIschemic attackHospital stayCohort studyCommon complicationHospital dischargePericardial effusionCardiorespiratory failurePrimary outcomeProcedural characteristicsComplicationsPatientsHospitalStudy periodBackground ComplicationsPotential disparitiesFibrillation
2021
Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
Wheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. JAMA Network Open 2021, 4: e2137288. PMID: 34870678, PMCID: PMC8649845, DOI: 10.1001/jamanetworkopen.2021.37288.Peer-Reviewed Original ResearchConceptsDOAC useAnticoagulant prescriptionOral anticoagulantsUS cliniciansMedicare beneficiariesNational clinical practice guidelinesElevated bleeding riskOral anticoagulant prescriptionsRetrospective cohort studyDirect oral anticoagulantsClinical practice guidelinesUS Medicare beneficiariesInternal medicine physiciansNumber of cliniciansAnticoagulant prescribingDOAC prescriptionsUnique cliniciansBleeding riskCohort studyAnticoagulant strategiesPrescription claimsPractice guidelinesMAIN OUTCOMEMost indicationsMedicare population
2020
Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction
Jackevicius CA, Krumholz HM, Ross JS, Koh M, Chong A, Austin PC, Stukel TA, Azizi P, Ko DT. Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction. Canadian Journal Of Cardiology 2020, 36: 1633-1640. PMID: 32416066, DOI: 10.1016/j.cjca.2020.01.024.Peer-Reviewed Original ResearchConceptsPrior myocardial infarctionMyocardial infarctionStable patientsPopulation-based observational studyAngina 1 yearDeath/hospitalizationHistory of revascularisationBeta-blocker useMajor cardiovascular eventsHospital discharge diagnosisUse of BBsIndividual end pointsContemporary clinical trialsYears of ageCardiovascular eventsIndex dateCohort studyComposite outcomeBB useHeart failureMedian agePrimary outcomeClinical outcomesAtrial fibrillationDischarge diagnosis
2017
National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999–2013
Freeman JV, Wang Y, Akar J, Desai N, Krumholz H. National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999–2013. Circulation 2017, 135: 1227-1239. PMID: 28148599, DOI: 10.1161/circulationaha.116.022388.Peer-Reviewed Original Research
2016
Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation
Dodson JA, Petrone A, Gagnon DR, Tinetti ME, Krumholz HM, Gaziano JM. Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. JAMA Cardiology 2016, 1: 65. PMID: 27437657, PMCID: PMC5600874, DOI: 10.1001/jamacardio.2015.0345.Peer-Reviewed Original ResearchConceptsTraumatic intracranial bleedingIntracranial bleedingInternational normalized ratioIschemic strokeAtrial fibrillationIncidence rateAnticonvulsant useWarfarin therapyNormalized ratioRisk factorsOlder adultsVeterans AffairsCox proportional hazards regressionVA electronic medical recordsMean patient agePatients 75 yearsRetrospective cohort studyClinical Modification codesCoronary artery diseaseProportional hazards regressionService claims dataVA administrative dataSignificant predictorsHealth care professionalsElectronic medical records
2006
Recursive partitioning–based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery
Sedrakyan A, Zhang H, Treasure T, Krumholz HM. Recursive partitioning–based preoperative risk stratification for atrial fibrillation after coronary artery bypass surgery. American Heart Journal 2006, 151: 720-724. PMID: 16504639, DOI: 10.1016/j.ahj.2005.05.010.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryAtrial fibrillationLow-risk groupAggressive prophylaxisRelative riskPredictors of AFArtery bypass graft surgeryCoronary artery bypass surgeryRisk of AFYale-New Haven HospitalOnly ejection fractionPreoperative atrial fibrillationBypass graft surgeryArtery bypass surgeryCoronary artery diseasePreoperative risk stratificationHigh-risk groupHeart disease severityPossible adverse eventsOlder age subgroupsArrhythmia prophylaxisGraft surgeryProphylactic therapyAdverse eventsBypass surgery
2005
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: Evidence from randomized clinical trials
Sedrakyan A, Treasure T, Browne J, Krumholz H, Sharpin C, van der Meulen J. Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: Evidence from randomized clinical trials. Journal Of Thoracic And Cardiovascular Surgery 2005, 129: 997-1005. PMID: 15867772, DOI: 10.1016/j.jtcvs.2004.07.042.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAmiodaroneAnti-Arrhythmia AgentsAtrial FibrillationAtrial FlutterCalcium Channel BlockersDigitalis GlycosidesEvidence-Based MedicineFemaleFlecainideHospital CostsHumansLength of StayMagnesiumMaleMiddle AgedMorbidityPostoperative ComplicationsPremedicationPreoperative CareRandomized Controlled Trials as TopicTachycardia, SupraventricularThoracic Surgical ProceduresTreatment OutcomeConceptsPostoperative atrial tachyarrhythmiasGeneral thoracic surgeryAtrial tachyarrhythmiasCalcium channel blockersRandomized clinical trialsThoracic surgeryClinical trialsSingle small trialLonger hospital stayUse of digitalisPossible adverse eventsFixed-effects modelAntiarrhythmic medicationsPharmacologic prophylaxisHospital stayProphylactic regimenAdverse eventsCommon complicationPulmonary edemaSignificant morbidityUnblinded trialCochrane DatabaseProphylactic useSmall trialsPlacebo control
2003
Gender differences in recovery after coronary artery bypass surgery
Vaccarino V, Lin ZQ, Kasl SV, Mattera JA, Roumanis SA, Abramson JL, Krumholz HM. Gender differences in recovery after coronary artery bypass surgery. Journal Of The American College Of Cardiology 2003, 41: 307-314. PMID: 12535827, DOI: 10.1016/s0735-1097(02)02698-0.Peer-Reviewed Original ResearchConceptsPhysical functionCABG surgeryDepressive symptomsHospital readmissionCoronary artery bypass graft surgeryArtery bypass graft surgeryCoronary artery bypass surgeryBypass graft surgeryArtery bypass surgeryCongestive heart failureLow physical functionMore depressive symptomsFirst CABGGraft surgeryBaseline characteristicsBypass surgeryPatient characteristicsHeart failureIllness severityMedical recordsWorse outcomesClinical dataFemale genderHigh riskSide effects
2000
Evaluating Quality of Care for Patients With Heart Failure
Krumholz H, Baker D, Ashton C, Dunbar S, Friesinger G, Havranek E, Hlatky M, Konstam M, Ordin D, Pina I, Pitt B, Spertus J. Evaluating Quality of Care for Patients With Heart Failure. Circulation 2000, 101: e122-40. PMID: 10736303, DOI: 10.1161/01.cir.101.12.e122.Peer-Reviewed Original ResearchAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAnticoagulantsAspirinAtrial FibrillationData CollectionDigoxinExercise TherapyFee-for-Service PlansHeart FailureHumansInformation ServicesLength of StayOutcome and Process Assessment, Health CarePatient Education as TopicPractice Guidelines as TopicPractice Patterns, Physicians'Quality of Health CareReferral and ConsultationStroke VolumeUnited StatesVentricular Dysfunction, Left
1998
Warfarin Use Following Ischemic Stroke Among Medicare Patients With Atrial Fibrillation
Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M. Warfarin Use Following Ischemic Stroke Among Medicare Patients With Atrial Fibrillation. JAMA Internal Medicine 1998, 158: 2093-2100. PMID: 9801175, DOI: 10.1001/archinte.158.19.2093.Peer-Reviewed Original ResearchConceptsUse of warfarinAtrial fibrillationIschemic strokeRecurrent strokeWarfarin useElderly patientsPrincipal diagnosisMedicare patientsLower riskConnecticut Peer Review OrganizationRegimen of warfarinElderly stroke patientsRisk of strokeAcute myocardial infarctionHigh-risk populationHigh rateChart reviewPeer review organizationsStroke patientsMyocardial infarctionWarfarin sodiumPatientsWarfarinFibrillationAnticoagulation
1997
Warfarin use among patients with atrial fibrillation.
Brass L, Krumholz H, Scinto J, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28: 2382-9. PMID: 9412618, DOI: 10.1161/01.str.28.12.2382.Peer-Reviewed Original ResearchConceptsAtrial fibrillationAdditional vascular risk factorsConnecticut Peer Review OrganizationRate of strokeVascular risk factorsStroke preventionWarfarin anticoagulationChart reviewElderly patientsRelative contraindicationPeer review organizationsRisk factorsMedicare patientsAnticoagulationHigh riskPatientsWarfarinFibrillationStrokeContraindicationsAspirinReview organizationsPopulation sampleHospitalizationMonths
1993
Cardioversion from Atrial Fibrillation without Prolonged Anticoagulation with Use of Transesophageal Echocardiography to Exclude the Presence of Atrial Thrombi
Manning W, Silverman D, Gordon S, Krumholz H, Douglas P. Cardioversion from Atrial Fibrillation without Prolonged Anticoagulation with Use of Transesophageal Echocardiography to Exclude the Presence of Atrial Thrombi. New England Journal Of Medicine 1993, 328: 750-755. PMID: 8437595, DOI: 10.1056/nejm199303183281102.Peer-Reviewed Original ResearchConceptsAtrial thrombusLong-term anticoagulationAtrial fibrillationTransesophageal echocardiographyOral anticoagulationEarly cardioversionTransthoracic echocardiographyLong-term oral anticoagulationConventional noninvasive techniquesOral anticoagulation therapyShort-term anticoagulationPresence of thrombusAnticoagulation therapyEmbolic eventsQualifying patientsConsecutive patientsProlonged anticoagulationSuccessful cardioversionSinus rhythmAnticoagulationCardioversionEchocardiographyPatientsThrombusFibrillation